[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-cervical-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-cervical-cancer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,93,120,142,163,186],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100644680","circulating-cfdna-and-hpv-as-prognostic-biomarkers-for-first-line-recurrent-metastatic-cervical-cancer-100644680",false,"NCT07673211","Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer","A Prognostic Research on First-Line Recurrent and Metastatic Cervical Cancer Using Circulating Cell-Free DNA and Human Papillomavirus Detection","Inclusion Criteria:\n\n1. Histopathologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;\n2. Patients with first recurrent or metastatic cervical cancer (including primary stage IVB disease);\n3. Received standard first-line therapy (TP\u002FTC regimen plus immunotherapy ± bevacizumab);\n4. Achieved complete response (CR) following standard first-line treatment;\n5. Archived pathological biopsy specimens of recurrent\u002Fmetastatic lesions prior to treatment available in our hospital;\n6. Participated in clinical trials of pharmaceutical therapy for first-line recurrent\u002Fmetastatic cervical cancer conducted at our institution;\n7. Voluntarily participates in this study and provides written informed consent;\n8. Agrees to serial peripheral blood collection at scheduled time points;\n9. Willing to complete scheduled follow-up visits;\n10. Aged ≥ 18 years old.\n\nExclusion Criteria:\n\n1. History of other malignant tumors within the past 2 years;\n2. Pregnant or breastfeeding women;\n3. Severe concomitant diseases, including: cardiovascular diseases (e.g., uncontrolled heart failure, unstable angina, etc.); pulmonary diseases (e.g., severe chronic obstructive pulmonary disease, interstitial pneumonia and other conditions impairing respiratory function); hepatic and renal dysfunction (e.g., decompensated liver cirrhosis, severe renal failure requiring dialysis, etc.);\n4. Refusal to sign informed consent;\n5. Refusal to undergo serial blood collection.","FEMALE","18 Years",{"count":19,"type":20},60,"ESTIMATED","3 Years","OBSERVATIONAL","Primary Objective of this study: To investigate the correlation between longitudinal quantitative dynamics of circulating tumor DNA (ctDNA) and HPV-derived cell-free DNA (HPV cfDNA) in peripheral blood and clinical prognosis among patients with recurrent and metastatic cervical cancer who achieved complete response following standard first-line systemic therapy.",[25,26,27],"Cervical Cancer","Recurrent Cervical Cancer","Metastatic Cervical Cancer",[29,30,31,32,33],"Cervical cancer","ctDNA","HPV cfDNA","Complete response","Prognosis","NOT_YET_RECRUITING","2026-06-23",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":20},"2026-06",{"date":42,"type":20},"2029-12",{"name":44,"class":45},"Zhejiang Cancer Hospital","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":66,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100644252","reirradiation-and-total-ablative-strategies-for-recurrent-gynecologic-cancer-100644252","NCT07667192","Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer","REGYNERA(Dia)TION: An Ambispective International Multicenter Patient Registry of Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Malignancies","Regynera-RT","Inclusion Criteria:\n\n* \\- Age 18 years or older at the time of reirradiation or prospective enrollment.\n* Histologically confirmed gynecologic malignancy, including uterine, cervical, vaginal, vulvar, ovarian, fallopian tube, primary peritoneal, or rare gynecologic primary.\n* Documented prior radiotherapy delivered as part of previous treatment.\n* Recurrent or progressive disease for which reirradiation and\u002For total ablative strategy has been delivered, is ongoing, or is planned according to local multidisciplinary decision-making.\n* Recurrence or progression documented by imaging, clinical examination, pathology, and\u002For multidisciplinary tumor board assessment according to institutional practice.\n* Availability of minimum essential data, including prior radiotherapy information, date of reirradiation or planned reirradiation, disease extent at reirradiation, and at least one follow-up, outcome, or survival-status record for retrospective patients.\n* For prospective patients, written informed consent where required by local regulations and ethics approval.\n\nExclusion Criteria:\n\n* No evidence of prior radiotherapy.\n* No reirradiation or clinically meaningful local ablative radiotherapy component delivered or planned.\n* Insufficient minimum data preventing assignment of reirradiation date, disease extent, or survival\u002Ffollow-up status.\n* Exclusively polymetastatic disease with more than 5 active non-regional lesions treated without a meaningful local reirradiation or total ablative component, unless included in an exploratory non-core substudy approved by the steering committee.\n* Prospective refusal of consent when consent is required by local law or ethics approval.",{"count":55,"type":20},500,"5 Years","REGYNERA(dia)TION is an international, multicenter, ambispective observational patient registry of adults with recurrent gynecologic malignancies after prior radiotherapy who are treated or planned for reirradiation and\u002For total ablative strategies as part of routine clinical care. The registry does not assign treatment. Radiotherapy technique, dose, systemic therapy, surgery, metastasis-directed therapy, imaging, and follow-up are selected by the treating multidisciplinary team according to local standards and patient-specific factors. The registry will collect harmonized retrospective and prospective data on disease characteristics, prior radiotherapy, recurrence pattern, reirradiation or ablative treatment exposure, response, progression, survival, severe treatment-related morbidity, fistula events, and patient-reported outcomes where available.",[59,60,26,61,62,63,64,65],"Recurrent Gynecologic Cancer","Recurrent Uterine Cancer","Recurrent Vaginal Cancer","Recurrent Vulvar Cancer","Recurrent Ovarian Cancer","Recurrent Fallopian Tube Cancer","Primary Peritoneal Cancer",[67,68,69,70,71,72,73,74,75,76,77,78,79,80,81],"Reirradiation","Radiotherapy","Brachytherapy","External Beam Radiotherapy","Stereotactic Body Radiotherapy","Proton Therapy","Intraoperative Radiotherapy","Total Ablative Strategy","Oligometastatic Recurrence","Metastasis-Directed Therapy","Patient Registry","Radiographic Progression-Free Survival","Treatment-Related Adverse Events","Fistula","Overall survival","RECRUITING","2026-06-20",{"date":85,"type":38},"2026-06-24",{"date":87,"type":38},"2026-06-11",{"date":89,"type":20},"2036-12",{"name":91,"class":45},"Affidea Nu-med Center of Oncological DIagnostics and Therapy",1,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":103,"phases":104,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":92},"100629244","phase-2-pd-1-programmed-death-1-versus-pd-l1-programmed-death-ligand-1-immune-check-point-inhibitors-combined-with-chemotherapy-with-or-without-bevacizumab-in-patients-with-metastatic-persistent-or-recurrent-cervical-cancer-100629244","NCT07472153","PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer","To Validate, Develop and Implement The Scope of Medical Care for Metastatic, Persistent and Recurrent Cervical Cancer Using The Method of Chemoimmunotargeted Therapy","Inclusion Criteria:\n\n* Age ≥18-≤75 years.\n* Histologically confirmed diagnosis.\n* One of the forms of the cervical cancer:\n\n  1. Metastatic cervical cancer (stage IVB according to FIGO (International Federation of Gynaecology and Obstetrics) 2018);\n  2. Persistent cervical cancer (primary incurability after radical treatment for stages IIB-IVA cervical cancer according to FIGO 2018);\n  3. Reccurent cervical cancer (first recurrence after completed radical treatment for IA-IVB cervical cancer according to FIGO 2018).\n* Availability of material for determining PD-L-1 expression for immunotherapy candidates.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* No contraindications to chemotherapy, immunotherapy, or bevacizumab.\n* Signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Presence of another active malignant invasive neoplasm.\n* Pregnancy or lactation period.","75 Years",{"count":102,"type":20},120,"INTERVENTIONAL",[105,106],"PHASE2","PHASE3","This is a randomized trial evaluating the results of using of PD-1 and PD-L1 immune checkpoint inhibitors combined with chemotherapy, with or without bevacizumab, in patients with metastatic, persistent, and recurrent cervical cancer.",[27,109,26],"Persistent Cervical Cancer","2026-05-26",{"date":112,"type":38},"2026-05-28",{"date":114,"type":38},"2025-07-01",{"date":116,"type":20},"2033-06-30",{"name":118,"class":119},"N.N. Alexandrov National Cancer Centre","OTHER_GOV",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":103,"phases":129,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":92},"100625139","phase-3-a-study-of-shr-a2102-versus-investigators-choice-of-chemotherapy-in-patients-with-platinum-based-chemotherapy-and-pd-l1-inhibitor-treatment-failed-recurrent-or-metastatic-cervical-cancer-100625139","NCT07418749","A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer","An Open-label, Randomized, Controlled, Multicenter, Phase III Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer","Inclusion Criteria:\n\n1. Participate in the study voluntarily, sign the informed consent form.\n2. Histologically or cytologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma that is deemed unsuitable for radical surgery and\u002For radical radiotherapy or chemoradiotherapy.\n3. Provide primary or metastatic tumor samples.\n4. At least one measurable lesion (RECIST version 1.1).\n5. ECOG 0\\~ 1.\n6. With adequate organ functions.\n7. Expected overall survival is ≥12 weeks.\n\nExclusion Criteria:\n\n1. With known untreated or active central nervous system (CNS) tumor metastasis, or a history of or current leptomeningeal metastasis.\n2. With symptomatic, poorly controlled, or moderate-to-severe pleural effusion, pericardial effusion, or ascites.\n3. With a history of or concurrent other malignant tumor(s).\n4. Participants with gastrointestinal perforation or fistula, urogenital fistula, or those at risk of fistula within 3 months prior to randomization.\n5. With known or suspected interstitial lung disease.\n6. With intestinal obstruction or signs\u002Fsymptoms suggestive of intestinal obstruction within 3 months prior to randomization.\n7. With poorly controlled cardiac clinical symptoms or diseases.\n8. Experienced arterial\u002Fvenous thromboembolic events within 3 months prior to randomization.\n9. With severe infections occurring within 1 month prior to randomization.\n10. With active hepatitis B (defined as positive hepatitis B surface antigen \\[HBsAg\\] test and hepatitis B virus \\[HBV\\] DNA ≥500 IU\u002FmL at screening) or active hepatitis C (defined as positive hepatitis C virus antibody \\[HCV-Ab\\] test and detectable hepatitis C virus \\[HCV\\] RNA at screening).\n11. With active tuberculosis infection within 1 year prior to randomization, or a history of active tuberculosis infection more than 1 year ago without proper treatment.\n12. With a history of immunodeficiency, including a positive human immunodeficiency virus (HIV) test, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.\n13. Have received systemic anti-tumor therapy within 28 days prior to randomization.\n14. With uncontrolled psychiatric disorders, or known history of alcoholism, drug abuse, or substance dependence, incarceration, or other conditions that may affect the completion of study procedures.\n15. Any other condition that, in the judgment of the investigator, may increase the risk associated with study participation, interfere with the interpretation of study results, or make the participant unsuitable for the study.",{"count":128,"type":20},398,[106],"The main objective of this study is to evaluate the efficacy of SHR-A2102 versus investigator's choice of chemotherapy in patients with platinum-based chemotherapy and PD-(L)1 inhibitor treatment failed recurrent or metastatic cervical cancer.",[26,27],"2026-04-03",{"date":134,"type":38},"2026-04-06",{"date":136,"type":38},"2026-03-30",{"date":138,"type":20},"2028-12",{"name":140,"class":141},"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","INDUSTRY",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":100,"enrollmentInfo":149,"targetDuration":151,"studyType":22,"phases":4,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":4},"100607308","ql706--chemo--bevacizumab-in-anti-pd-l1-resistant-rm-cervical-cancer-100607308","NCT07186868","QL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R\u002FM Cervical Cancer","A Prospective, Open-Label, Single-Arm Study of Iparomlimab and Toripalimab Plus Nab-Paclitaxel With or Without Bevacizumab in Recurrent\u002FMetastatic Cervical Cancer Progressed on Anti-PD-(L)1 Therapy","Inclusion Criteria:\n\n* Female patients aged 18 to 75 years.\n* Histologically, pathologically, or radiologically confirmed recurrent or metastatic cervical cancer.\n* At least one measurable lesion as defined by RECIST 1.1 (non-nodal lesion longest diameter ≥10 mm or lymph node short axis ≥15 mm).\n* ECOG performance status of 0 or 1.\n* Life expectancy ≥12 weeks.\n* Disease progression after receiving at least one prior anti-PD-1\u002FPD-L1 monoclonal antibody therapy (alone or in combination).\n* Adequate organ function within 14 days before enrollment:\n\nAbsolute neutrophil count (ANC) \\>1.5 × 10⁹\u002FL Platelets \\>100 × 10⁹\u002FL Hemoglobin \\>100 g\u002FL Serum total bilirubin \\\u003C1.5 × ULN ALT and AST \\\u003C3 × ULN Creatinine clearance (CCr) \\>60 mL\u002Fmin\n\n* Voluntarily sign the informed consent form, able to understand and comply with study requirements.\n\nExclusion Criteria:\n\n* Known allergy to any component of the study drugs.\n* Prior treatment with any CTLA-4 targeting medication.\n* Adverse reactions from previous anti-cancer therapy have not recovered to ≤ Grade 1 (per CTCAE v5.0) (except for toxicities without safety risk per investigator's judgment, e.g., alopecia).\n* History of other malignancies within the past 5 years, except for cured malignancies.\n* Severe comorbid conditions, including but not limited to:\n\nExtensive interstitial lung disease requiring medication. Active or uncontrolled infections (e.g., tuberculosis, HIV). Decompensated liver disease, active hepatitis, or active bleeding. History of cerebrovascular accident or pulmonary embolism. Active, known, or suspected autoimmune diseases. Active infection requiring systemic anti-infective therapy.\n\n* Ascites with depth \\>5 cm measured by ultrasound or CT, OR ascites causing severe symptoms (e.g., abdominal distension, dyspnea, circulatory dysfunction) significantly impacting physical function or study safety.\n* Pregnant, planning pregnancy, or lactating women.\n* Any other condition deemed by the investigator as unsuitable for participation in this study.",{"count":150,"type":20},25,"2 Years","This is a clinical research study for women with recurrent or metastatic cervical cancer whose disease has progressed after prior treatment with a PD-1\u002FPD-L1 inhibitor immunotherapy.\n\nThe study will evaluate the effectiveness and safety of a new combination treatment consisting of iparvolimab and tuvonralimab (QL1706)-a dual-targeting immunotherapy drug-along with chemotherapy (nab-paclitaxel) with or without bevacizumab, an anti-angiogenic drug that may help prevent tumor growth.\n\nApproximately 25 participants will be enrolled in this open-label, single-arm study. All participants will receive the study treatment for up to 6 cycles, followed by maintenance therapy until disease progression, unacceptable side effects, or other reasons for stopping treatment.\n\nThe main goal of the study is to see how many patients respond to the treatment (Objective Response Rate, ORR). Other goals include measuring how long the response lasts, how long patients live without the cancer getting worse, and overall survival. Safety and quality of life will also be closely monitored.\n\nThis study is for women aged 18-75 who have previously received PD-1\u002FPD-L1 treatment and whose cancer has worsened. Participants must be in generally good health with adequate organ function and no other active cancers.\n\nThe study will be conducted at a single center in China. All participants will provide written informed consent before joining the study.",[26,27],"2025-09-16",{"date":156,"type":38},"2025-09-22",{"date":158,"type":20},"2025-10-15",{"date":160,"type":20},"2027-12-30",{"name":162,"class":45},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":100,"enrollmentInfo":170,"targetDuration":4,"studyType":103,"phases":172,"briefSummary":173,"conditions":174,"keywords":175,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":92},"100606181","phase-2-the-efficacy-and-safety-rc48-plus-ql1706-in-second-line-treatment-of-her2-expressing-recurrent-cc-100606181","NCT07172217","The Efficacy and Safety RC48 Plus QL1706 in Second-Line Treatment of HER2-Expressing Recurrent CC","Clinical Study on the Efficacy and Safety of Disitamab Vedotin Combined With Iparomlimab and Tuvonralimab in the Second-Line Treatment of HER2-Expressing Recurrent Cervical Cancer","Inclusion Criteria:\n\n* Voluntarily enroll in the study and sign a written informed consent form;\n* Female patients aged 18 to 75 years (inclusive);\n* Histologically or cytologically confirmed primary cervical squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, or small cell (neuroendocrine) cervical cancer;\n* Progressive disease or recurrent disease after first-line treatment for recurrent cervical cancer;\n* Subjects can provide tumor specimens (paraffin blocks, formalin-fixed paraffin-embedded \\[FFPE\\] sections, or fresh tissue sections) from the primary or metastatic site for HER2 detection, with HER2 immunohistochemistry (IHC) test results of IHC 1+, 2+, or 3+ (previous test results confirmed by the investigator are also acceptable);\n* Presence of at least one evaluable lesion (per RECIST 1.1 criteria);\n* Expected survival time ≥ 6 months;\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 to 1;\n* For female patients of childbearing potential (i.e., premenopausal or not surgically sterilized), the serum pregnancy test result within 7 days before the first administration of the study drug must be negative; and reliable contraceptive measures must be used during the study drug administration period and within 60 days after the last dose;\n* Normal function of major organs, meeting the following criteria:\n\nLeft ventricular ejection fraction (LVEF) ≥ 50%; Hemoglobin (Hb) ≥ 9 g\u002FdL; Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹\u002FL; Platelets (PLT) ≥ 100 × 10⁹\u002FL; Serum total bilirubin (TBIL) ≤ 1.5 × upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN in the absence of liver metastasis, and ALT and AST ≤ 5 × ULN in the presence of liver metastasis; Serum creatinine (Scr) ≤ 1.5 × ULN, or creatinine clearance (CrCl) ≥ 40 mL\u002Fmin calculated by the Cockcroft-Gault formula.\n\nExclusion Criteria:\n\n* History of malignant tumors other than cervical cancer, except for the following two situations:\n\n  1. Patients who have received potentially curative treatment and have no evidence of the disease for 5 years;\n  2. Basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, cervical carcinoma in situ, and other carcinoma in situ that have been successfully treated with resection;\n* Previous allogeneic stem cell or solid organ transplantation;\n* Previous systemic anti-tumor therapy (including traditional Chinese medicine with anti-tumor indications) completed less than 4 weeks before the first administration of the study drug, or patients whose adverse events caused by previous treatment have not recovered to ≤ Grade 1 according to the Common Terminology Criteria for Adverse Events (CTCAE) (except for alopecia and pigmentation);\n* Vaccination with live vaccines within 4 weeks before the start of study drug administration, or planned receipt of any vaccines (except COVID-19 vaccines) during the study period;\n* Previous or current history of congenital or acquired immunodeficiency diseases;\n* Previous treatment with other antibody-drug conjugates (ADCs);\n* Patients with known or suspected history of allergy to recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugates and anti-PD-1 drugs of the same class, or history of hypersensitivity to chimeric\u002Fhumanized antibodies or fusion proteins, or allergy to the excipients of the study drug;\n* Other significant clinical and laboratory abnormalities that the investigator deems may affect safety evaluation, such as uncontrolled diabetes mellitus, chronic kidney disease, peripheral neuropathy of Grade 2 or higher (per CTCAE V5.0), abnormal thyroid function, etc.;\n* Heart failure of New York Heart Association (NYHA) Class 3 or higher;\n* Severe infection in active stage or with poor clinical control; active infections include:\n\n  1. Positive for human immunodeficiency virus (HIV) (HIV1\u002F2 antibodies);\n  2. Active hepatitis B (positive for hepatitis B surface antigen \\[HBsAg\\], or hepatitis B virus deoxyribonucleic acid \\[HBV DNA\\] \\> 2000 IU\u002Fml with abnormal liver function);\n  3. Active hepatitis C (positive for hepatitis C virus \\[HCV\\] antibodies, or HCV ribonucleic acid \\[HCV RNA\\] ≥ 10³ copies\u002Fml with abnormal liver function);\n  4. Active tuberculosis;\n  5. Other uncontrolled active infections (Grade \\> 2 per CTCAE V5.0); Unrecovered from surgery (e.g., presence of unhealed surgical incisions or severe postoperative complications);\n* Other circumstances deemed unsuitable for enrollment by the investigator.",{"count":171,"type":20},33,[105],"This is a single-arm study. The efficacy and safety of Disitamab Vedotin combined with Apalutamide and Toripalimab in the second-line treatment of HER2-expressing recurrent cervical cancer are evaluated based on the following indicators:\n\nPrimary evaluation indicator: Objective Response Rate (ORR)\n\nSecondary evaluation indicators:\n\nEfficacy-related indicators: Progression-Free Survival (PFS), Disease Control Rate (DCR), Duration of Response (DOR), Overall Survival (including median Overall Survival \\[mOS\\] and 1-year, 2-year, 3-year Overall Survival rates) Safety-related indicators: Adverse Events (AEs) and Serious Adverse Events (SAEs).",[26],[176],"RC48;QL1706;HER2-Expressing;Recidivation; Cervical Cancer","2025-09-12",{"date":179,"type":38},"2025-09-15",{"date":181,"type":20},"2025-10-01",{"date":183,"type":20},"2028-12-31",{"name":185,"class":45},"Qilu Hospital of Shandong University",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":192,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":82,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":208},"100575354","study-on-disease-characteristics-and-treatment-in-locally-advanced-or-recurrent--metastatic-cervical-cancer-in-italy-100575354","NCT06771193","Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent \u002F Metastatic Cervical Cancer in Italy","RETRACE Study - Retrospective Observational Study Evaluating Disease Characteristics and Treatment Landscape of High-risk Locally Advanced (LA) or Recurrent \u002F Metastatic (R\u002FM) Cervical Cancer in Italy","RETRACE","Inclusion Criteria:\n\n* Patient (or their legally acceptable representatives) must have signed and dated the Informed Consent \\& Privacy Form (ICF)\n* Age ≥18 years\n* Diagnosis of a cervical cancer\n* Locally advanced stage (not suitable for curative surgery) or recurrent or metastatic disease\n* Any treatment received between January 2018 and December 2021 for advanced disease\n\nExclusion Criteria:\n\n* Patients participating in a pharmacological clinical trial for the treatment of advanced disease\n* Patients who participated in a clinical trial\n* Patients who were administered with Pembrolizumab, Olaparib or Levantinib or medications from these class of drugs",{"count":195,"type":20},200,"Multicenter, Observational, Retrospective charts review. Observational study with descriptive purpose only. Retrospective data capture in consecutive patients diagnosed with CC who attended the Oncologic Clinics from Jan 2018 to Dec 2021 (using medical records, either electronic or not), inserted in eCRF and analyzed.",[25,198,26,27],"Locally Advanced Cervical Cancer","2025-07-16",{"date":201,"type":38},"2025-07-20",{"date":203,"type":38},"2024-12-17",{"date":205,"type":20},"2025-12",{"name":207,"class":141},"MSD Italia S.r.l.",11]